Amyloid‐β but not tau accumulation is strongly associated with longitudinal cognitive decline

Abstract

AbstractObjectiveAlzheimer's disease (AD) pathology is featured by the extracellular accumulation of amyloid‐β (Aβ) plaques and intracellular tau neurofibrillary tangles in the brain. We studied whether Aβ and tau accumulation are independently associated with future cognitive decline in the AD continuum.MethodsData were acquired from the Alzheimer's Disease Neuroimaging Initiative (ADNI) public database. A total of 1272 participants were selected based on the availability of Aβ‐PET and CSF tau at baseline and of those 777 participants with follow‐up visits.ResultsWe found that Aβ‐PET and CSF tau pathology were related to cognitive decline across the AD clinical spectrum, both as potential predictors for dementia progression. Among them, Aβ‐PET (A + T− subjects) is an independent reliable predictor of longitudinal cognitive decline in terms of ADAS‐13, ADNI‐MEM, and MMSE scores rather than tau pathology (A − T+ subjects), indicating tau accumulation is not closely correlated with future cognitive impairment without being driven by Aβ deposition. Of note, a high percentage of APOE ε4 carriers with Aβ pathology (A+) develop poor memory and learning capacity. Interestingly, this condition is not recurrence in terms of the ADNI‐MEM domain when adding APOE ε4 status. Finally, the levels of Aβ‐PET SUVR related to glucose hypometabolism more strongly in subjects with A + T− than A − T+ both happen at baseline and longitudinal changes.ConclusionsIn conclusion, Aβ‐PET alone without tau pathology (A + T−) measure is an independent reliable predictor of longitudinal cognitive decline but may nonetheless forecast different status of dementia progression. However, tau accumulation alone without Aβ pathology background (A − T+) was not enough to be an independent predictor of cognitive worsening.